April 22nd 2024
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Determining the Molecular Profile of BTK Inhibitor Responsive DLBCL Tumors
January 4th 2022In an interview with Targeted Oncology, Mark Roschewski, MD, discussed precision medicine in diffuse large B-cell lymphoma and using acalabrutinib in a pre-chemotherapy window to better understand its potential benefit.
Read More
Part 2: Loncastuximab as a Third-Line Therapy for Relapsed/Refractory DLBCL
December 15th 2021During a live virtual event, Paolo Caimi, MD, discussed the toxicity and dosage of loncastuximab tesirine as a third-line therapy for diffuse large B-cell lymphoma before receiving chimeric antigen receptor T-cell therapy.
Read More
Interim Analysis of LOTIS-3 Shows Promising Results in R/R DLBCL
December 11th 2021The use of ibrutinib plus loncastuximab tesirine induced encouraging anti-tumor activity and a manageable safety profile in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma, according to results from an interim analysis of the LOTIS-3 trial.
Read More
Part 3: Third-Line Use of Loncastuximab for Relapsed/Refractory DLBCL
December 6th 2021During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.
Read More
Part 3: Kline Discusses the Use of Tafasitamab in Certain Patients with R/R DLBCL
November 16th 2021While antibody-drug conjugates have shown promise in patients with relapsed/refractory diffuse large B-cell lymphoma, there are other options that can help patients before moving on to CAR T-cell therapy.
Read More
Roundtable Discussion: Hill Discusses Systemic Therapy for Relapsed/Refractory DLBCL
November 12th 2021Eleven months after completing therapy for diffuse large B-cell lymphoma, a 43-year-old patients reported fever, night sweats, and back pain, and a palpable lymph node was discovered in her left groin.
Read More
Part 3: Polatuzumab Vedotin Plus Bendamustine and Rituximab Shows Promise in Patients With DLBCL
November 1st 2021The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.
Read More
Roundtable Discussion: Persky and Participants Review CAR T-Cell Therapy in DLBCL
October 31st 2021Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.
Read More
Part 2: Shah Discusses Challenges in Using Lenalidomide Plus Tafasitamab for Patients With DLBCL
October 28th 2021Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.
Read More